|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: Recent
advances and future directions. Oncologist. 13 Suppl 1:5–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Popat S, Reinmuth N, De Ruysscher
D, Kerr KM and Peters S: ESMO Guidelines Working Group: Metastatic
non-small cell lung cancer (NSCLC): ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25
Suppl 3:iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: OAK Study Group: Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK):
A phase 3, open-label, multicentre randomised controlled trial.
Lancet. 389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sznol M and Chen L: Antagonist antibodies
to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human
cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soria JC, Marabelle A, Brahmer JR and
Gettinger S: Immune checkpoint modulation for non-small cell lung
cancer. Clin Cancer Res. 21:2256–2262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramalingam S, Hui R, Gandhi L, Carcereny
E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Leighl N, Aggarwal C,
et al: P2.39: Long-term OS for patients with advanced NSCLC
enrolled in the KEYNOTE-001 study of pembrolizumab: Track:
Immunotherapy. J Thorac Oncol. 11(10S): S241–S242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matter-Walstra K, Schwenkglenks M, Aebi S,
Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R and
Gautschi O: Swiss Group for Clinical Cancer Research: A
cost-effectiveness analysis of nivolumab versus docetaxel for
advanced nonsquamous NSCLC including PD-L1 testing. J Thorac Oncol.
11:1846–1855. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Langer CJ, Gadgeel SM, Borghaei H,
Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins
RG, Stevenson JP, Jalal SI, et al: KEYNOTE-021 investigators:
Carboplatin and pemetrexed with or without pembrolizumab for
advanced, non-squamous non-small-cell lung cancer: A randomised,
phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol.
17:1497–1508. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: POPLAR Study Group: Atezolizumab
versus docetaxel for patients with previously treated
non-small-cell lung cancer (POPLAR): A multicentre, open-label,
phase 2 randomised controlled trial. Lancet. 387:1837–1846. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pearce EL, Walsh MC, Cejas PJ, Harms GM,
Shen H, Wang LS, Jones RG and Choi Y: Enhancing CD8 T-cell memory
by modulating fatty acid metabolism. Nature. 460:103–107. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rolf J, Zarrouk M, Finlay DK, Foretz M,
Viollet B and Cantrell DA: AMPKα1: A glucose sensor that controls
CD8 T-cell memory. Eur J Immunol. 43:889–896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Araki K and Ahmed R: AMPK: A metabolic
switch for CD8+ T-cell memory. Eur J Immunol. 43:878–881. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eikawa S, Nishida M, Mizukami S, Yamazaki
C, Nakayama E and Udono H: Immune-mediated antitumor effect by type
2 diabetes drug, metformin. Proc Natl Acad Sci USA. 112:1809–1814.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scharping NE, Menk AV, Whetstone RD, Zeng
X and Delgoffe GM: Efficacy of PD-1 blockade is potentiated by
metformin-induced reduction of tumor hypoxia. Cancer Immunol Res.
5:9–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gruenbacher G and Thurnher M: Mevalonate
metabolism in cancer. Cancer Lett. 356:192–196. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee YG, Lee JH, Jang JS and Kim JH:
Prognostic benefit of taking statin and/or metformin in elderly
patients with advanced non-small cell lung cancer: A nationwide
population-based epidemiologic study. J Clin Oncol. 36:10045. 2018.
View Article : Google Scholar
|
|
21
|
Cancer Therapy Evaluation Program, .
Common Toxicity Criteria. Version 2.0. DCTD, NCI, NIH, DHHS.
March;1998.https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf
|
|
22
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ku GY, Yuan J, Page DB, Schroeder SE,
Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP and
Wolchok JD: Single-institution experience with ipilimumab in
advanced melanoma patients in the compassionate use setting:
Lymphocyte count after 2 doses correlates with survival. Cancer.
116:1767–1775. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Delyon J, Mateus C, Lefeuvre D, Lanoy E,
Zitvogel L, Chaput N, Roy S, Eggermont AM, Routier E and Robert C:
Experience in daily practice with ipilimumab for the treatment of
patients with metastatic melanoma: An early increase in lymphocyte
and eosinophil counts is associated with improved survival. Ann
Oncol. 24:1697–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ferrucci PF, Ascierto PA, Pigozzo J, Del
Vecchio M, Maio M, Cappellini Antonini GC, Guidoboni M, Queirolo P,
Savoia P, Mandalà M, et al: Baseline neutrophils and derived
neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic
melanoma patients receiving ipilimumab. Ann Oncol. 27:732–738.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gubin MM, Zhang X, Schuster H, Caron E,
Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et
al: Checkpoint blockade cancer immunotherapy targets
tumour-specific mutant antigens. Nature. 515:577–581. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
da Silva Barreira R, Laird ME, Yatim N,
Fiette L, Ingersoll MA and Albert ML: Dipeptidylpeptidase 4
inhibition enhances lymphocyte trafficking, improving both
naturally occurring tumor immunity and immunotherapy. Nat Immunol.
16:850–858. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chamoto K, Chowdhury PS, Kumar A, Sonomura
K, Matsuda F, Fagarasan S and Honjo T: Mitochondrial activation
chemicals synergize with surface receptor PD-1 blockade for T
cell-dependent antitumor activity. Proc Natl Acad Sci USA.
114:E761–E770. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nielsen SF, Nordestgaard BG and Bojesen
SE: Statin use and reduced cancer-related mortality. N Engl J Med.
367:1792–1802. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cardwell CR, Hicks BM, Hughes C and Murray
LJ: Statin use after colorectal cancer diagnosis and survival: A
population-based cohort study. J Clin Oncol. 32:3177–3183. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu O, Eberg M, Benayoun S, Aprikian A,
Batist G, Suissa S and Azoulay L: Use of statins and the risk of
death in patients with prostate cancer. J Clin Oncol. 32:5–11.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bernhart E, Damm S, Wintersperger A,
Nusshold C, Brunner AM, Plastira I, Rechberger G, Reicher H,
Wadsack C, Zimmer A, et al: Interference with distinct steps of
sphingolipid synthesis and signaling attenuates proliferation of
U87MG glioma cells. Biochem Pharmacol. 96:119–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pardo OE, Lesay A, Arcaro A, Lopes R, Ng
BL, Warne PH, McNeish IA, Tetley TD, Lemoine NR, Mehmet H, et al:
Fibroblast growth factor 2-mediated translational control of IAPs
blocks mitochondrial release of Smac/DIABLO and apoptosis in small
cell lung cancer cells. Mol Cell Biol. 23:7600–7610. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pardo OE, Wellbrock C, Khanzada UK, Aubert
M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout
IT, et al: FGF-2 protects small cell lung cancer cells from
apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.
EMBO J. 25:3078–3088. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kozar K, Kaminski R, Legat M, Kopec M,
Nowis D, Skierski JS, Koronkiewicz M, Jakóbisiak M and Golab J:
Cerivastatin demonstrates enhanced antitumor activity against human
breast cancer cell lines when used in combination with doxorubicin
or cisplatin. Int J Oncol. 24:1149–1157. 2004.PubMed/NCBI
|
|
37
|
Holstein SA and Hohl RJ: Synergistic
interaction of lovastatin and paclitaxel in human cancer cells. Mol
Cancer Ther. 1:141–149. 2001.PubMed/NCBI
|
|
38
|
Feleszko W and Jakóbisiak M: Lovastatin
augments apoptosis induced by chemotherapeutic agents in colon
cancer cells. Clin Cancer Res. 6:1198–1199. 2000.PubMed/NCBI
|
|
39
|
Rodriguez OGA, Barron FB, Padilla MÁS,
Ramirez-Tirado LA, Flores-Estrada D, Cruz-Rico G, Jiménez MJA and
Zorrilla AFC: Combination of metformin plus TKI vs. TKI alone in
EGFR(+) LUNG adenocarcinoma: A randomized phase II study. J Clin
Oncol. 36:9013. 2018. View Article : Google Scholar
|
|
40
|
Kim HJ, Lee S, Chun KH, Jeon JY, Han SJ,
Kim DJ, Kim YS, Woo JT, Nam MS, Baik SH, et al: Metformin reduces
the risk of cancer in patients with type 2 diabetes: An analysis
based on the Korean National Diabetes Program Cohort. Medicine
(Baltimore). 97:e00362018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rao S, Porter DC, Chen X, Herliczek T,
Lowe M and Keyomarsi K: Lovastatin-mediated G1 arrest is through
inhibition of the proteasome, independent of hydroxymethyl
glutaryl-CoA reductase. Proc Natl Acad Sci USA. 96:7797–7802. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB
and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in
simvastatin induced S-phase cell cycle arrest and apoptosis in
multiple myeloma cells. Eur J Pharmacol. 670:356–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cafforio P, Dammacco F, Gernone A and
Silvestris F: Statins activate the mitochondrial pathway of
apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis.
26:883–891. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS,
Cai DQ, Wu Z, Qin JW, Yu YH and Kim SK: HMG-CoA reductase
inhibitors induce apoptosis of lymphoma cells by promoting ROS
generation and regulating Akt, Erk and p38 signals via suppression
of mevalonate pathway. Cell Death Dis. 4:e5182013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Spampanato C, De Maria S, Sarnataro M,
Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F:
Simvastatin inhibits cancer cell growth by inducing apoptosis
correlated to activation of Bax and down-regulation of BCL-2 gene
expression. Int J Oncol. 40:935–941. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Moghim S, Sarikhani E, Esfahani Nasr B and
Faghri J: Identification of nontuberculous mycobacteria species
isolated from water samples using phenotypic and molecular methods
and determination of their antibiotic resistance patterns by E-test
method, in Isfahan, Iran. Iran J Basic Med Sci. 15:1076–1082.
2012.PubMed/NCBI
|
|
47
|
Bennaceur K, Atwill M, Al Zhrany N,
Hoffmann J, Keavney B, Breault D, Richardson G, von Zglinicki T,
Saretzki G and Spyridopoulos I: Atorvastatin induces T cell
proliferation by a telomerase reverse transcriptase (TERT) mediated
mechanism. Atherosclerosis. 236:312–320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ulivieri C, Fanigliulo D, Benati D, Pasini
FL and Baldari CT: Simvastatin impairs humoral and cell-mediated
immunity in mice by inhibiting lymphocyte homing, T-cell activation
and antigen cross-presentation. Eur J Immunol. 38:2832–2844. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roy K, Ghosh M, Pal TK, Chakrabarti S and
Roy S: Cholesterol lowering drug may influence cellular immune
response by altering MHC II function. J Lipid Res. 54:3106–3115.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Blank CU, Haanen JB, Ribas A and
Schumacher TN: CANCER IMMUNOLOGY. The ‘cancer immunogram’. Science.
352:658–660. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Seckl MJ, Ottensmeier CH, Cullen M, Schmid
P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife
KM, et al: Multicenter, phase III, randomized, double-blind,
placebo-controlled trial of pravastatin added to first-line
standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin
Oncol. 35:1506–1514. 2017. View Article : Google Scholar : PubMed/NCBI
|
